AGL 38.34 Increased By ▲ 0.32 (0.84%)
AIRLINK 214.00 Increased By ▲ 16.64 (8.43%)
BOP 9.86 Increased By ▲ 0.32 (3.35%)
CNERGY 6.50 Increased By ▲ 0.59 (9.98%)
DCL 9.17 Increased By ▲ 0.35 (3.97%)
DFML 38.40 Increased By ▲ 2.66 (7.44%)
DGKC 100.75 Increased By ▲ 3.89 (4.02%)
FCCL 36.15 Increased By ▲ 0.90 (2.55%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 14.49 Increased By ▲ 1.32 (10.02%)
HUBC 134.20 Increased By ▲ 6.65 (5.21%)
HUMNL 13.69 Increased By ▲ 0.19 (1.41%)
KEL 5.65 Increased By ▲ 0.33 (6.2%)
KOSM 7.30 Increased By ▲ 0.30 (4.29%)
MLCF 45.30 Increased By ▲ 0.60 (1.34%)
NBP 61.25 Decreased By ▼ -0.17 (-0.28%)
OGDC 232.25 Increased By ▲ 17.58 (8.19%)
PAEL 41.00 Increased By ▲ 2.21 (5.7%)
PIBTL 8.53 Increased By ▲ 0.28 (3.39%)
PPL 202.99 Increased By ▲ 9.91 (5.13%)
PRL 40.00 Increased By ▲ 1.34 (3.47%)
PTC 28.29 Increased By ▲ 2.49 (9.65%)
SEARL 107.70 Increased By ▲ 4.10 (3.96%)
TELE 8.73 Increased By ▲ 0.43 (5.18%)
TOMCL 36.16 Increased By ▲ 1.16 (3.31%)
TPLP 13.89 Increased By ▲ 0.59 (4.44%)
TREET 24.38 Increased By ▲ 2.22 (10.02%)
TRG 61.15 Increased By ▲ 5.56 (10%)
UNITY 34.70 Increased By ▲ 1.73 (5.25%)
WTL 1.72 Increased By ▲ 0.12 (7.5%)
BR100 12,240 Increased By 513.2 (4.38%)
BR30 38,279 Increased By 1902.2 (5.23%)
KSE100 113,957 Increased By 4443.4 (4.06%)
KSE30 36,067 Increased By 1553.8 (4.5%)

A Japanese medical team has found that a form of antibiotic may prevent cancer patients from losing hair during chemotherapy, a doctor involved in the research said Monday.
Toshiyuki Sakai said his team had found "alopestatin" reduced hair loss by 70 percent when used on rats also given etoposide anti-cancer drugs. Etoposide is widely used to treat lung and other cancers but can cause hair loss.
Sakai, professor at Kyoto Prefectural University of Medicine, said his team was hoping to put the agent to practical use in the future. "I want people to know that few studies have been made on reducing side-effects of anti-cancer drugs," he said.
"This field is lagging behind (the development of cancer drugs) but is still important for patients' quality of life."
The study, which was outlined at an academic meeting in Japan last week, is still ongoing, and the chances are "low at the moment" that alopestatin will be commercialised soon, he said.
No clinical tests are yet in sight, but one possible use for humans would be to apply it to the head in the period when hair loss is most likely to occur during chemotherapy, he added.

Copyright Agence France-Presse, 2007

Comments

Comments are closed.